Preventative Treatment Trials (Adjuvant)

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

18 trials found

Imatinib
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery (Z9000)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00025246 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country


Imatinib
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor (RTOG-S-0132)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00028002 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country


Imatinib
Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery (ACOSOG-Z9001)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00041197 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country


Imatinib
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor (EORTC-62024)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00103168 Conditions: Gastrointestinal Stromal Tumor
Status:
 Unknown
Site
City
State
Country


Imatinib
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00116935 Conditions: GIST Sarcoma
Status:
 Completed
Site
City
State
Country
Helsinki University Central Hospital Helsinki Finland
Lund University Hospital Lund Sweden


Imatinib
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (Japan CSTI571BJP07)
Phase: 
4 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00171977 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country
Site name unknown, Tokyo Tokyo Japan


Imatinib
Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation (ROK CSTI571BKR08)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00278876 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country


Imatinib
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST (MDACC)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00500188 Conditions: GIST
Status:
 Completed
Site
City
State
Country
MD Anderson Cancer Center Houston TX USA


Imatinib
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00867113 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
University of Colorado Aurora CO USA
Washington Cancer Institute Washington DC USA
Northeast Georgia Cancer Center (ACORN) Athens GA USA
NE Georgia Health Systems Gainesville GA USA
Kootenai Cancer Center Coeur d'Alene ID USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
North Shore University Health Systems Evanston IL USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Southern Nevada Cancer Research center Las Vegas NV USA
Dartmouth-Hitchcock Medical Center Lebanon NH USA
Memorial Sloan Kettering New York NY USA
Montefiore North Bronx NY USA
Queens Cancer Center of Queens Regional Hospital Jamaica NY USA
Duke University Durham NC USA
Wake Forrest Winston-Salem NC USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Fox Chase Cancer Center Philadelphia PA USA
Pennsylvania State University Hershey PA USA
Roger Williams Medical Center Providence RI USA
Kingsport Hematolog Oncology Kingsport TN USA
MD Anderson Cancer Center Houston TX USA
South Texas Oncology Hematology San Antonio TX USA
Virginia Oncology Associates Norfolk VA USA
Emory University Hospital Midtown (EUHM) Atlanta GA USA
Wayne State University Wertz Clinical Cancer Center Detroit MI USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA


Imatinib
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (IMAGE) (Novartis CSTI571BIC08)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT01172548 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country
Site name unknown - Algiers Algiers Algeria
Site name unknown - Cairo Cairo Egypt
Site name unknown Delhi New Delhi Delhi India
Site name unknown Mumbai Mumbai Mumbai India
Site name unknown - Pune Pune India
Site name unknown - Ahmedabad Ahmedabad India
Site name unknown - Amman Amman Jordan
Site name unknown - Beirut Beirut Lebanon
Site name unknown - Saida Saida Lebanon
Site name unknown - Moscow Moscow Russia
Site name unknown - Irkutsk Irkutsk Russia
Site name unknown - Kazan Kazan Russia
Site name unknown - Kursk Kursk Russia
Site name unknown - Omsk Omsk Russia
Site name unknown - St. Petersburg St. Petersburg Russia
Site name unknown - Yekaterinburg Yekaterinburg Russia
Site name unknown - Riyadh Riyadh Saudi Arabia
Site name unknown - Pretoria Pretoria South Africa
Site name unknown - Johannesburg Johannesburg South Africa
Site name unknown - Kaohsiung Kaohsiung County Taiwan
Site name unknown - Taichung Taichung Taiwan
Site name unknown - Tainan Tainan City Taiwan
Site name unknown - Taipei Taipei Taiwan
Site name unknown - Taoyuan Taoyuan County Taiwan
Site name unknown - Songkla Songkla Thailand
Site name unknown Bangkok Bankok Thailand
Site name unknown - Tunis Tunis Tunisia
Site name unknown - Ankara Ankara Turkey
Site name unknown - Istanbul Istanbul Turkey
Site name unknown - Izmir Izmir Turkey
Site name unknown - Cairo Cairo Egypt


Imatinib
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT02260505 Conditions: Gastrointestinal Stromal Tumor
Status:
 Completed
Site
City
State
Country
Centre Léon Bérard Lyon Rhone France
Institut Paoli-Calmette Marseille Bouches du Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Hôpital Jean Minjoz Besancon Doubs France
Institut Bergonie Bordeaux Gironde France
Hopital Europeen Georges Pompidou Paris Ile de France France
St. Herblain Saint-Herblain Loire Atlantique France
Centre Oscar Lambret - Lille Lille Nord France
Institut de Cancérologie Neuwirth Saint Priest en Jarez Loire France
Hopital Robert Debre Reims Marne France
Institut Gustave Roussy Villejuif Val de Narne France
Hôpital St Antoine Paris France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Centre Régional de Lutte contre le Cancer de Montpellier Montpellier Herault France
Institut de Cancérologie de Lorraine Vandoeuvre-les-Nancy Meurthe et Moselle France
CHRU Strasbourg - Hôpital Hautepierre Strasbourg France
Centre George Francois Leclerc Dijon Bourgogne-Franche-Comté France


Imatinib
Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (ABILITY)
Phase: 
1 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT02185937 Conditions: Gastrointestinal Stromal Tumor
Status:
 Terminated
Site
City
State
Country
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands


Imatinib
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT02413736 Conditions: Gastrointestinal Stromal Tumor
Status:
 Active, not recruiting
Site
City
State
Country
Helsinki University Central Hospital Helsinki Finland
Dept. of Oncology, Skane University Lund Sweden
Dept. of Oncology, Sahlgrenska University Hospital Gothenburg Sweden
Onkologiska Kliniken, Norrlands Universitetssjukhus Umea Sweden
Dept. of Oncology, Linkoping University Linkoping Sweden
Orebro University Hospital, Örebro Orebro Sweden
Karolinska University Hospital Solna Sweden
Karolinska University Hospital Solna Sweden
Turku University Hospital, Turku Turku Finland
Tampere University Hospital, Tampere Tampere Finland
Oulu University Hospital Oulu Finland
Kuopio University Hospital, Kuopio Kuopio Finland
Satakunta Central Hospital Pori, Pori Finland
Norwegian Radium Hospital Oslo Norway
Dept of Oncology, Haukeland University Hospital Bergen Norway
Department of Oncology, St Olav Hospital Trondheim Norway
Department of Oncology, Tromso University Hospital Tromso Norway
Copenhagen University Hospital Copenhagen Denmark
Arhus University Hospital Arhus Denmark
University Hospital La Paz Madrid Spain
Hospital Son Espases, Palma Palma Malorca Spain
Hospital Universitari Vall d'Hebrón Barcelona Spain
Hospital San Pau Barcelona Spain
Hospital General Universitario de Valencia Valencia Spain
CO L'Hospitalet - Hospital Duran i Reynals Barcelona Spain
Hospital Germans Trias i Pujol Badalona Spain
Hospital Universitario Gregorio Maranon Madrid Spain
Instituto Valenciano de Oncologia Valencia Spain
Hospital Universitario Puerta de Hierro de Majadahonda Madrid Spain
Hospital Universitario de Canarias Tenerife Spain
Hospital Universitario Virgen de la Macarena Sevilla Spain
Hospital Virgen del Rocio Sevilla Spain
Hospital Alvaro Cunqueiro, Vigo Vigo Spain
Hospital Clinico Universitario Virgen de la Victoria Malaga Spain
Cambridge University Hospitals Cambridge UK
Royal Marsden Hospital - Chelsea London UK
University College Hospital London UK
Beatson West of Scotland Cancer Centre Glasgow UK
Weston Park Hospital Sheffield UK
Nottingham University Hospitals NHS Trust - Nottingham City Hospital Nottingham UK
Christie Hospital NHS Trust Manchester Lancashire UK
Birmingham Heartlands Hospital Birmingham UK
Helios Klinikum Berlin-Buch Berlin Germany
Krankenhaus Nordwest Frankfurt Germany
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Otto-von-Guericke-Universität, Magdeburg Magdeburg Germany
MVZ Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg Hamburg Germany
Klinikum Großhadern, München Munich Germany
Medizinische Universitätsklinik, Abteilung II, Tübingen Tubingen Germany
Universitätsklinikum Würzburg, Klinik & Poliklinik für Allgemein- und Viszeralchirurgie, Gefäß- und Kinderchirurgie, Wurzburg Germany
Leiden University Leiden Netherlands
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands
University Medical Center Groningen Groningen Netherlands
Allgemeines Krankenhaus Vienna Austria
Landesklinikum Wiener Neustadt Wiener Neustadt Germany
Medizinische Universitatsklinik Graz Graz Austria
Center GH Diaconesses-Croix Saint Simon Paris France


Imatinib
The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT02924714 Conditions: Gastrointestinal Stromal Tumor
Status:
 Suspended
Site
City
State
Country
Oslo University Hospital Oslo Norway


Surgery
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Phase: 
Drug Category: None
NCT#:
 NCT04557969 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
Site
City
State
Country
National Cancer Institute Bethesda MD USA


Imatinib
Imatinib TDM (Therapeutic Drug Monitoring) in GIST
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT05493215 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
Site
City
State
Country
University of Kentucky/Markey Cancer Center Lexington KY USA


ddPCR
Cross-Platform Biomarker Program for Establishment and Validation of Liquid Biopsy for Clinical Decision Making in resectable gastrointestinal stromal tumour (GIST)
Phase: 
Drug Category: none
NCT#:
 Conditions: Gastrointestinal Stromal Tumor
Status:
 Not yet recruiting
Site
City
State
Country
Helios Klinikum Bad Saarow Bad Saarow Germany
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Helios Klinikum Berlin-Buch Berlin Germany
University medical center Klinik für Hämatologie und Onkologie Lubeck Germany
University medical center Hämatologie, Zelltherapie und Medizinische Onkologie Dresden Germany
University medical center Sarkomzentrum UMM Mannheim Mannheim Germany
Sarkomzentrum Berlin-Brandenburg Berlin Germany
University medical center SarKUM, Zentrum für Knochen- und Weichteiltumore Munchen Germany
University medical center Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Hanover Germany
University medical center UniversitätsKrebszentrum Göttingen Gotingen Germany


Imatinib
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT05385549 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea


18 trials found